Table 1. Summary of clinical features .... | American Society of Hematology

Table 1.

Summary of clinical features

	All patients	HCV⁻patients	HCV⁺ patients^*
Patients, no.	56	11	45
Female-male ratio, no.	21:35	5:6	16:29
Age at final biopsy, y, mean (range)	21.4 (12-39)	17.7	22.3
Duration between biopsies, y, mean (range)	3.3 ± 0.9 (1.2-4.9)	3.5 ± 0.9	3.3 ± 0.9
Duration of deferiprone therapy before final biopsy, y, mean (range)^†	3.1 ± 1.0 (0.7-4.6)	3.4 ± 1.1	3.0 ± 1.0

	All patients	HCV⁻patients	HCV⁺ patients^*
Patients, no.	56	11	45
Female-male ratio, no.	21:35	5:6	16:29
Age at final biopsy, y, mean (range)	21.4 (12-39)	17.7	22.3
Duration between biopsies, y, mean (range)	3.3 ± 0.9 (1.2-4.9)	3.5 ± 0.9	3.3 ± 0.9
Duration of deferiprone therapy before final biopsy, y, mean (range)^†	3.1 ± 1.0 (0.7-4.6)	3.4 ± 1.1	3.0 ± 1.0

One patient became HCV⁺ after the first biopsy and for purposes of analysis is considered HCV⁺.

The biopsies were obtained prior to onset of therapy. Data are presented as mean ± SD.